Waters Corporation announced the appointment of Wei Jiang to its Board of Directors, effective July 14, 2021. Jiang currently serves as Executive Vice President and President, Bayer Pharmaceuticals Region China & APAC and President, Bayer Group Greater China.

Dr Flemming Ornskov, Chairman of the Board, said, “We are excited to welcome Jiang to the Board and know that we will benefit from his operating experience and transformation expertise. Jiang has an outstanding record of driving results in regions that represent key growth opportunities for Waters, including China and other Asia-Pacific markets. We believe he is a valuable addition to the Board at this pivotal time for Waters.”

Dr Udit Batra, President and CEO, Waters Corporation, commented, “Jiang’s results-driven experience will bring perspective to the Board that directly aligns with Waters’ strategy to accelerate growth and innovation. We look forward to his insights as we continue to further strengthen our focus on serving customers in the fast-growing and cutting-edge pharma market in Greater China and beyond.”

Jiang said, “China’s pharma, biopharma and natural products markets are experiencing a surge in growth and innovation. I can’t think of a company better positioned than Waters to serve these customers with the world-class analytical technologies and services that Waters is so well known for. I am honoured to join the Board and contribute to the momentum of the Company’s ongoing transformation.”

Jiang is Executive Vice President and President, Bayer Pharmaceuticals Region China & APAC and President, Bayer Group Greater China, where he is a Member of the Pharmaceuticals Executive Committee and responsible for pharma business in China and APAC. He previously held various senior positions at AstraZeneca, culminating in his role as Senior Vice President, China operations. Prior to that, Jiang served as Managing Director, China operations at Guidant Corporation and in various roles at Eli Lilly & Company including Marketing Director, China Operations. He currently serves on the boards of China Red Cross and R&D Based Pharmaceuticals association. He received his undergraduate degree in economics and finance at Indiana State University and a B.BA. in business administration and finance from Campbell University in North Carolina.